White Paper
The Impact of Biosimilar Competition in Europe 2024
Jan 24, 2025
Download

To mark the 10th edition of the 'Impact of Biosimilar Competition in Europe' publication by IQVIA, this report will take a more forward-looking view on the upcoming opportunities and challenges for biosimilar competition in Europe.

Biosimilars remain a critical part of the European healthcare system and are able to balance pharmaceutical spending by generating savings for payers, creating headroom for innovation, and expanding access to biologic therapy for patients. Since the first biosimilar was launched in 2006, biosimilar medicines have become a core component of an effective healthcare system, but latest information on the biosimilar pipeline signals future headwinds that were highlighted in previous reports and remain steadfast.

The report consists of novel observations on market conditions for 2024, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. Previous observations remain relevant and have been refined or referenced to align with the report's approach of sharing novel observations on the value of biosimilars, and the impact of competition that biosimilars provide in the European healthcare system.

Contact Us